Shutout! The Baseball Writers Association of America fails to elect anyone to the Hall of Fame


It’s possible that this year’s Hall of Fame ballot was the most stacked in the history of the institution.  It contained the all-time home run leader. It contained a seven-time Cy Young award winner who may have been the best pitcher in baseball history since the deadball era. It contained the best hitting catcher of all time. It contained a middle infielder who got to 3,000 hits while flashing superior defense and power. It sported a 609-home run hitter a 583-home run hitter, the second best leadoff hitter in the history of the game and at least five others who, had they been inducted, would not be close to the worst players to make the Hall of Fame.

And none of them got in. Not a one. For the first time since 1996, all candidates on the ballot failed to receive the requisite 75% required for induction.  The leading vote getter was Craig Biggio, who received 68% of the vote. Jack Morris received 67.7%, Jeff Bagwell received 59.6% of the vote, Mike Piazza 57.8% and Tim Raines at 52.2%. No other player received more than 50% of the vote. Roger Clemens received 37.6% of the vote and Barry Bonds received 36.2%. Each of those last two received totals far below even the most pessimistic predictions. The full results can be seen here.

The biggest takeaway from all of this: the Baseball Writers Association of America has, for the first time, unequivocally decided that the use of performance enhancing drugs is a disqualifier for induction to the Hall of Fame. It was suspected that this was the case given Mark McGwire and Rafael Palmeiro falling short in previous years, but there are some reasonable non-PED arguments against those fellows’ candidacies.  Not so with Bonds and Clemens. They were so good and so accomplished that, to paraphrase Bill James, you could cut them in half and have two hall of famers each. Maybe three, actually. Their exclusion is solely because a large portion of the electorate believes that one cannot take steroids and call Cooperstown home.

Which, while understandable, flies in the face of baseball history. There are almost certainly already steroids users in the Hall of Fame. Indeed, Hall of Fame voter and Washington Post columnist Thomas Boswell said on camera, in Ken Burns’ “Tenth Inning” that he witnessed a current Hall of Famer taking steroids during his playing career. Maybe his fellow voters ignored him. Maybe, since that player’s induction, whoever he is, their attitudes have changed. Either way, there is certainly now a historical inconsistency baked into the Hall of Fame.  And in no event can anyone who applauds today’s voting results do so on the basis of the Hall of Fame maintaining its purity, for its purity is pure fantasy.

But just as the BBWAA has now clearly stated that drug users are not wanted in the Hall of Fame, it has apparently likewise erected a near-impossible hurdle for those not associated with PEDs to bound, regardless of their merits.

Craig Biggio had 3,000 hits. Tim Raines was one of the best players of the 1980s. Curt Schilling has three World Series rings, was dominant in the playoffs, and was one of the best pitchers in all of baseball for several years when being a pitcher in baseball was about as hard as it has ever been.  While I disagree that we should keep the PED players out, I at least understand the impulse. What’s the point of keeping out guys like Biggio, Raines and Schilling? What’s the point of the Hall of Fame if no one can get in in a year as talent-rich as this one?

But that’s where we are. Not one of the players on the ballot made it in. The induction ceremony in Cooperstown, New York this summer will honor three men — Hank O’Day, Jacob Ruppert, and Deacon White — who were elected by the Veterans Committee last month.  All three of those men have been dead since the 1930s, so I don’t presume it will be a joyful gathering of family and friends reminiscing about their storied pasts. It’ll be more like a memorial service.

Which is somewhat appropriate given that, with their votes, the current electorate is, in this writer’s view, hastening the Hall of Fame to its doom.

Blue Jays narrow GM search to two candidates: Tony LaCava and Ross Atkins

Tony LaCava
AP Photo/Wilfredo Lee
1 Comment

Jon Heyman of CBS Sports reports that the Blue Jays have narrowed their search for a new general manager down to two candidates: current interim GM Tony LaCava, and Indians vice president of player personnel Ross Atkins. Former Jays GM Alex Anthopoulos resigned last month.

LaCava was promoted to interim GM on November 2 and has already made a handful of moves along with new president Mark Shapiro. The club acquired Jesse Chavez in a trade and signed pitchers Marco Estrada and J.A. Happ to multi-year deals.

Atkins worked under Shapiro in the Indians organization for 15 seasons, so it is no surprise that he is a finalist for the open GM position.

The Diamondbacks met with Johnny Cueto’s agent

AP Photo/David Goldman
1 Comment

Ken Rosenthal of FOX Sports reports that the Diamondbacks spoke with Bryce Dixon, the agent of free agent starter Johnny Cueto. However, Rosenthal notes that Cueto’s price tag is expected to exceed the Diamondbacks’ comfort level.

Cueto, 29, is one of a handful of highly touted starting pitchers in this offseason’s free agent class. He is joined by David Price and Zack Greinke, among others. Jordan Zimmermann inked a deal in the neighborhood of $110 million over five years with the Tigers on Sunday morning, which will serve as a barometer for Cueto.

Cueto finished the 2015 regular season, between the Reds and the Royals, with a 3.44 ERA and a 176/46 K/BB ratio over 212 innings. He made 13 shaky starts with the Royals, but outside of a shellacking in Game 3 of the ALCS against the Blue Jays, pitched well in the post-season. Cueto pitched a complete game in Game 2 of the World Series against the Mets, helping put the Royals up two games to none at the time.

As a result of switching teams during the season, Cueto was not eligible to receive a $15.8 million qualifying offer. This means that Cueto, unlike Zimmermann for example, does not come attached with draft pick compensation.

Red Sox president Dave Dombrowski is reportedly trying to trade Hanley Ramirez

Hanley Ramirez
AP Photo/Charles Krupa, File

Nick Cafardo provides this interesting nugget in his Sunday notes column at the Boston Globe

Hanley Ramirez, 1B-DH, Red Sox — There’s now talk in the front office that Dave Dombrowski is trying to move Ramirez in a deal. The Mariners, Orioles, and Angels seem to be the targets, and all three make sense.

Cafardo notes that “there are huge hurdles to cross” before a trade could happen — like how much of Hanley’s remaining salary the Red Sox would have to eat and what positions the soon-to-be 32-year-old is able to play defensively at this point in his career.

Boston’s higher-ups have asked Ramirez to learn first base and drop 20 pounds this winter. Whatever team is looking to acquire him would probably have to be comfortable with him serving primarily as a designated hitter.

Hanley is owed $68.2 million over the next three seasons and he carries a $22 million vesting option for 2019. He batted just .249/.291/.426 in 105 games this past year.

Ben Zobrist is the “Mets’ No. 1 target”

Ben Zobrist
AP Photo/Charlie Riedel

Ben Zobrist posted a cool .809 OPS (120 OPS+) in 126 games this summer between Oakland and Kansas City while appearing defensively at second base, third base, and both corner outfield positions.

His steady bat and defensive versatility make him a fit for just about every club in Major League Baseball, and the defending National League champions are among the teams in hot pursuit …

It’s a little odd to see the rebuilding Braves listed there given that Zobrist is 34 years old, but Rosenthal says the interest stems from a “desire for him to serve as [a] model for younger players” as the club prepares to open a new ballpark in 2017. Wasn’t that supposed to be Nick Markakis‘ job?

Zobrist and his agent Alan Nero are believed to be seeking a four-year deal.